Replies to post #800654 on NorthWest Biotherapeutics Inc (NWBO)

[Survivor2012]

I believe the MAA "approval announcement" will include an "adjuvant," like partnership, merger, acquisition, buyout or major BPs/Hospitals franchise agreement. It may also include the EDEN certification or maybe the big enchilada--AGNOSTIC applicability!! The science "says" DCVax-L will work for all solid tumors (Real World Data and a presentation by Dr Bosch, summer 2024) and so does common sense!

[maverick_1]

WHY HAVEN'T THEY SUBMITTED ANYTHING TO NICE YET?
Re 10baggerz

Very likely based on pure memory recall

10baggerz missed MAESTRO’s 2024 comments:
“Having good discussions with NICE”
IF NWBO has not submitted to NICE: Why the above ⚡️recall

Validation from Larry Smith (just the two of us met him face to face for an hour in 1984)

Northwest Biotherapeutics: CEO Linda Powers’ In-depth Company Overview at the Annual Meeting
POSTED by LARRY SMITH on JUL 8, 2024 •

Applying for Reimbursement

Following MAA approval, they will need to go through the process of applying for reimbursement. In the UK, gatekeeper is NICE. CEO Powers says that NICE has been absolutely supportive in their dealings with NWBO and she cannot say enough wonderful things about the relationship so far. They have been reaching out to NWBO every couple of months to check on the status of things. She couldn't imagine a government agency that's been as supportive of as they have been. NWBO will need to do a health economics model that justifies the cost benefits of the DCVax-L treatment.

$nwbo I have taken the transcript from Linda Power’s comments at the annual meeting and edited and organized them to make for easier reading. It contains a wealth of valuable information. I have also included my key takeaways. The report is free . https://t.co/xRORGeau42

— Larry Smith (@SmithOnStocks1) July 8, 2024

Take a look at the 2024 ASM transcription to VERIFY

Any reply BOGUS without DOCUMENTATION

DIFFERENT STROKES for DIFFERENT FOLKS